Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood (2022) 139 (12): 1908–1919.

https://doi.org/10.1182/blood.2021013290

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R. Popat, Qaiser Bashir, Chitra M. Hosing, Yago Nieto, Amin M. Alousi, Muzaffar H. Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E. Champlin, Partow Kebriaei

Blood (2020) 136 (15): 1786–1789.

https://doi.org/10.1182/blood.2019004685

Published: 2020

Includes: Supplemental data

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Constantine S. Tam, Susan O’Brien, William Plunkett, William Wierda, Alessandra Ferrajoli, Xuemei Wang, Kim-Anh Do, Jorge Cortes, Issa Khouri, Hagop Kantarjian, Susan Lerner, Michael J. Keating

Blood (2014) 124 (20): 3059–3064.

https://doi.org/10.1182/blood-2014-06-583765

Published: 2014

Includes: Supplemental data

Journal Articles

Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia

Fleur M. Aung, MD, Benjamin Lichtiger, MD PhD, Amin Alousi, MD, Sairah Ahmed, MD, Paolo Anderlini, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Stefan O. Ciurea, MD, Roy B Jones, PhD MD, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Betul Oran, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Issa Khouri, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Uday R Popat, MD

Blood (2013) 122 (21): 5449.

https://doi.org/10.1182/blood.V122.21.5449.5449

Published: 2013

Journal Articles

Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Sai Ravi Pingali, MD, Rima M Saliba, PhD, Veronica R. Smith, APN, Farzaneh Maadani, Kehinde U.A. Adekola, MBBS, Uday R Popat, MD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Issa Khouri, MD, Partow Kebriaei, MD, Stefan O. Ciurea, MD, Paolo Anderlini, MD, Nina Shah, MD, Yago Nieto, MD, PhD, Richard E Champlin, MD, Chitra M. Hosing, MD

Blood (2013) 122 (21): 4515.

https://doi.org/10.1182/blood.V122.21.4515.4515

Published: 2013

Journal Articles

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Blood (2013) 122 (21): 2167.

https://doi.org/10.1182/blood.V122.21.2167.2167

Published: 2013

Journal Articles

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

Sai Ravi Pingali, MD, Milton Denai, M S, Antonio Di Stasi, MD, Partow Kebriaei, MD, Uday R Popat, MD, Amin Alousi, MD, Paolo Anderlini, MD, Simrit Parmar, MD, Chitra M. Hosing, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Sairah Ahmed, MD, Betul Oran, MD, Elizabeth J Shpall, MD, Issa Khouri, MD, Marina Konopleva, MD, PhD, Gheath Alatrash, D.O., Ph.D., Richard E Champlin, MD, Stefan O. Ciurea, MD

Blood (2013) 122 (21): 4523.

https://doi.org/10.1182/blood.V122.21.4523.4523

Published: 2013

Journal Articles

The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT)

Armin Ghobadi, MD, Amir Hamdi, MD, Piyanuch Kongtim, MD, Denai Milton, Amin Alousi, MD, Paolo Anderlini, MD, Stefan O. Ciurea, MD, Betul Oran, MD, Issa Khouri, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Partow Kebriaei, MD, Uday R Popat, MD, Katy Rezvani, MD, PhD, Roy F Chemaly, MD, MPH, Elizabeth J Shpall, MD, Richard E Champlin, MD, Qaiser Bashir, MD

Blood (2013) 122 (21): 4531.

https://doi.org/10.1182/blood.V122.21.4531.4531

Published: 2013

Journal Articles

Double Hit Lymphoma: M.D. Anderson Experience

Yasuhiro Oki, MD, Mansoor Noorani, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Alma Rodriguez, M.D., Fredrick B Hagemeister, MD, Nathan Fowler, MD, Michael Wang, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Bouthaina S. Dabaja, MD, Chelsea Pinnix, M.D., Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Issa Khouri, MD, Jason R. Westin, MD, Luis E Fayad

Blood (2013) 122 (21): 1776.

https://doi.org/10.1182/blood.V122.21.1776.1776

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

Comorbidity and Outcomes for Patients Over Age 65 Years Treated with Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Henry J. Conter, MD, MSc, Nhu-Nhu Nguyen, Gabriela Rondon, MD, Julianne Chen, Elizabeth J Shpall, MD, Issa Khouri, MD, Sergio A Giralt, MD, Richard E. Champlin, Marcos DeLima, MD

Blood (2012) 120 (21): 2032.

https://doi.org/10.1182/blood.V120.21.2032.2032

Published: 2012

Journal Articles

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Betul Oran, MD, MS, Farhad Ravandi, MD, Hady Ghanem, MD, Issa Khouri, MD, Guillermo Garcia-Manero, MD, Michael S Mathisen, PharmD, Qaiser Bashir, MD, Rima M Saliba, PhD, Maria Khouri, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 2029.

https://doi.org/10.1182/blood.V120.21.2029.2029

Published: 2012

Journal Articles

A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd

Amin M. Alousi, M.D., Rima M Saliba, PhD, Julianne Chen, Borje S Andersson, MD, PhD, Issa Khouri, MD, Muzaffar H. Qazilbash, MD, Uday R. Popat, M.D., Chitra M. Hosing, M.D., Stefan O. Ciurea, Elizabeth J Shpall, MD, Roy B. Jones, MD, Ph.D., Partow Kebriaei, M.D., Yago Nieto, M.D., Ph.D., Paolo Anderlini, MD, Marcos DeLima, MD, Gabriela Rondon, Richard E. Champlin

Blood (2012) 120 (21): 4200.

https://doi.org/10.1182/blood.V120.21.4200.4200

Published: 2012

Journal Articles

Comparison of HLA Alleles in Follicular Lymphoma and Chronic Lymphocytic Leukemia Patients Referred for Allogeneic Stem Cell Transplantation

Fleur M. Aung, MD, Benjamin Litchtiger, MD, PhD, MBA, Issa Khouri, MD

Blood (2012) 120 (21): 4218.

https://doi.org/10.1182/blood.V120.21.4218.4218

Published: 2012

Journal Articles

High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies

Blood (2011) 118 (21): 3083.

https://doi.org/10.1182/blood.V118.21.3083.3083

Published: 2011

Journal Articles

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Paolo Anderlini, MD, Rima M Saliba, PhD, Celina Ledesma, B.S., Christina M Chancoco, Sandra Acholonu, Rosamar Valverde, Uday R Popat, MD, Chitra M Hosing, MD, Amin M Alousi, MD, Elizabeth J Shpall, MD, Yago Nieto, MD, PhD, Stefan O Ciurea, MD, Issa Khouri, MD, Richard Champlin, MD

Blood (2011) 118 (21): 3003.

https://doi.org/10.1182/blood.V118.21.3003.3003

Published: 2011

Journal Articles

Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,

Rima M Saliba, Ph.D., Alexandre Chiattone, MD, Alejandro Majlis, MD, Viviane C. Chiattone, RN, Gabriela Rondon, MD, Araci M. Sakashita, MD, Nelson Hamerschlak, MD, Jose Mauro Kutner, MD, PhD, Elizabeth J Shpall, MD, Paolo Anderlini, MD, Issa Khouri, MD, Muzaffar H Qazilbash, MD, Uday Popat, M.D., Richard Champlin, MD, Chitra M Hosing, MD, Marcos De Lima, MD

Blood (2011) 118 (21): 4058.

https://doi.org/10.1182/blood.V118.21.4058.4058

Published: 2011

Journal Articles

Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

Simrit Parmar, M.D., Gabriela Rondon, MD, Peter F Thall, PhD, Roland Bassett, Marcos De Lima, MD, Chitra M Hosing, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa Khouri, MD, Prasanth Ganesan, MD, Yvonne A Efebera, M.D., Richard Champlin, MD, Sergio A Giralt, MD

Blood (2011) 118 (21): 1944.

https://doi.org/10.1182/blood.V118.21.1944.1944

Published: 2011

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival

Uday Popat, M.D., Borje S Andersson, MD, PhD, Roland Bassett, Stefan Ciurea, Gabriela Rondon, MD, Amin M Alousi, MD, Paolo Anderlini, MD, Chitra Hosing, MD, Roy Jones, MD, PhD, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Issa Khouri, MD, Elizabeth J Shpall, MD, Srdan Verstovsek, MD, PhD, Muzaffar Qazilbash, MD, Marcos J de Lima, MD, Richard Champlin, MD

Blood (2011) 118 (21): 2006.

https://doi.org/10.1182/blood.V118.21.2006.2006

Published: 2011

NARROW

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia

Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT)

Double Hit Lymphoma: M.D. Anderson Experience

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Comorbidity and Outcomes for Patients Over Age 65 Years Treated with Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd

Comparison of HLA Alleles in Follicular Lymphoma and Chronic Lymphocytic Leukemia Patients Referred for Allogeneic Stem Cell Transplantation

High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,

Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only